In putting the finishing touches on a year that in many ways was not a great one for the medical device industry, I thought it might be appropriate to clean out the notebook on some thoughts on the previous year and – more to the point – the coming year.
Israeli device company IceCure Medical Ltd. scoped Cleveland for its U.S. headquarters, a move the company’s CEO hinted at in February.
IceCure’s lead product, IceSense3, freezes and destroys benign breast tumors using cryoblation, a technique using extreme cold to kill tissue. It won 510(k) clearance from the U.S. Food and Drug Administration late last year.
The company plans to open its U.S. headquarters at the Cleveland Clinic-led Global Cardiovascular Innovation Center campus on June 1, according to a statement from IceCure.